Nuclear Medicine Radiopharmaceuticals-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Nuclear Medicine Radiopharmaceuticals-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Nuclear Medicine Radiopharmaceuticals industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Global Nuclear Medicine Radiopharmaceuticals Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Nuclear Medicine Radiopharmaceuticals Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Diagnostic
Brachytherapy
Other Therapeutic
Global Nuclear Medicine Radiopharmaceuticals Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Oncology
Thyroid
Cardiology
Others
Global Nuclear Medicine Radiopharmaceuticals Market: Manufacturers Segment Analysis (Company and Product introduction, Nuclear Medicine Radiopharmaceuticals Sales Volume, Revenue, Price and Gross Margin):
Mallinckrodt
Isorad
Cardinal Health
Jubilant
Medi-Radiopharma
Comecer
Jaco
Ciaeriar
Advanced Molecular-imaging Solution
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Nuclear Medicine Radiopharmaceuticals-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Nuclear Medicine Radiopharmaceuticals industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
- Worldwide and Top 20 Countries Market Size of Nuclear Medicine Radiopharmaceuticals 2013-2017, and development forecast 2018-2023
- Main manufacturers/suppliers of Nuclear Medicine Radiopharmaceuticals worldwide and market share by regions, with company and product introduction, position in the Nuclear Medicine Radiopharmaceuticals market
- Market status and development trend of Nuclear Medicine Radiopharmaceuticals by types and applications
- Cost and profit status of Nuclear Medicine Radiopharmaceuticals, and marketing status
- Market growth drivers and challenges
Global Nuclear Medicine Radiopharmaceuticals Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Nuclear Medicine Radiopharmaceuticals Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Diagnostic
Brachytherapy
Other Therapeutic
Global Nuclear Medicine Radiopharmaceuticals Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Oncology
Thyroid
Cardiology
Others
Global Nuclear Medicine Radiopharmaceuticals Market: Manufacturers Segment Analysis (Company and Product introduction, Nuclear Medicine Radiopharmaceuticals Sales Volume, Revenue, Price and Gross Margin):
Mallinckrodt
Isorad
Cardinal Health
Jubilant
Medi-Radiopharma
Comecer
Jaco
Ciaeriar
Advanced Molecular-imaging Solution
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF NUCLEAR MEDICINE RADIOPHARMACEUTICALS
1.1 Definition of Nuclear Medicine Radiopharmaceuticals in This Report
1.2 Commercial Types of Nuclear Medicine Radiopharmaceuticals
1.2.1 Diagnostic
1.2.2 Brachytherapy
1.2.3 Other Therapeutic
1.3 Downstream Application of Nuclear Medicine Radiopharmaceuticals
1.3.1 Oncology
1.3.2 Thyroid
1.3.3 Cardiology
1.3.4 Others
1.4 Development History of Nuclear Medicine Radiopharmaceuticals
1.5 Market Status and Trend of Nuclear Medicine Radiopharmaceuticals 2013-2023
1.5.1 Global Nuclear Medicine Radiopharmaceuticals Market Status and Trend 2013-2023
1.5.2 Regional Nuclear Medicine Radiopharmaceuticals Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Nuclear Medicine Radiopharmaceuticals 2013-2017
2.2 Sales Market of Nuclear Medicine Radiopharmaceuticals by Regions
2.2.1 Sales Volume of Nuclear Medicine Radiopharmaceuticals by Regions
2.2.2 Sales Value of Nuclear Medicine Radiopharmaceuticals by Regions
2.3 Production Market of Nuclear Medicine Radiopharmaceuticals by Regions
2.4 Global Market Forecast of Nuclear Medicine Radiopharmaceuticals 2018-2023
2.4.1 Global Market Forecast of Nuclear Medicine Radiopharmaceuticals 2018-2023
2.4.2 Market Forecast of Nuclear Medicine Radiopharmaceuticals by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Nuclear Medicine Radiopharmaceuticals by Types
3.2 Sales Value of Nuclear Medicine Radiopharmaceuticals by Types
3.3 Market Forecast of Nuclear Medicine Radiopharmaceuticals by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Nuclear Medicine Radiopharmaceuticals by Downstream Industry
4.2 Global Market Forecast of Nuclear Medicine Radiopharmaceuticals by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Nuclear Medicine Radiopharmaceuticals Market Status by Countries
5.1.1 North America Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
5.1.2 North America Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
5.1.3 United States Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
5.1.4 Canada Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
5.1.5 Mexico Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
5.2 North America Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
5.3 North America Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
5.3.1 North America Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
5.3.2 North America Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
5.4 North America Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Nuclear Medicine Radiopharmaceuticals Market Status by Countries
6.1.1 Europe Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
6.1.2 Europe Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
6.1.3 Germany Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.4 UK Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.5 France Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.6 Italy Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.7 Russia Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.8 Spain Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.9 Benelux Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.2 Europe Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
6.3 Europe Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
6.3.1 Europe Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
6.3.2 Europe Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
6.4 Europe Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Nuclear Medicine Radiopharmaceuticals Market Status by Countries
7.1.1 Asia Pacific Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
7.1.2 Asia Pacific Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
7.1.3 China Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.1.4 Japan Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.1.5 India Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.1.6 Southeast Asia Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.1.7 Australia Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.2 Asia Pacific Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
7.3 Asia Pacific Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
7.3.1 Asia Pacific Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
7.3.2 Asia Pacific Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
7.4 Asia Pacific Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Nuclear Medicine Radiopharmaceuticals Market Status by Countries
8.1.1 Latin America Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
8.1.2 Latin America Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
8.1.3 Brazil Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
8.1.4 Argentina Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
8.1.5 Colombia Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
8.2 Latin America Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
8.3 Latin America Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
8.3.1 Latin America Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
8.3.2 Latin America Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
8.4 Latin America Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market Status by Countries
9.1.1 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
9.1.3 Middle East Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
9.1.4 Africa Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
9.2 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
9.3 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
9.3.2 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
9.4 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF NUCLEAR MEDICINE RADIOPHARMACEUTICALS
10.1 Global Economy Situation and Trend Overview
10.2 Nuclear Medicine Radiopharmaceuticals Downstream Industry Situation and Trend Overview
CHAPTER 11 NUCLEAR MEDICINE RADIOPHARMACEUTICALS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Nuclear Medicine Radiopharmaceuticals by Major Manufacturers
11.2 Production Value of Nuclear Medicine Radiopharmaceuticals by Major Manufacturers
11.3 Basic Information of Nuclear Medicine Radiopharmaceuticals by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Nuclear Medicine Radiopharmaceuticals Major Manufacturer
11.3.2 Employees and Revenue Level of Nuclear Medicine Radiopharmaceuticals Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 NUCLEAR MEDICINE RADIOPHARMACEUTICALS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Mallinckrodt
12.1.1 Company profile
12.1.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.1.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Mallinckrodt
12.2 Isorad
12.2.1 Company profile
12.2.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.2.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Isorad
12.3 Cardinal Health
12.3.1 Company profile
12.3.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.3.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Cardinal Health
12.4 Jubilant
12.4.1 Company profile
12.4.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.4.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Jubilant
12.5 Medi-Radiopharma
12.5.1 Company profile
12.5.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.5.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Medi-Radiopharma
12.6 Comecer
12.6.1 Company profile
12.6.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.6.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Comecer
12.7 Jaco
12.7.1 Company profile
12.7.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.7.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Jaco
12.8 Ciaeriar
12.8.1 Company profile
12.8.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.8.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Ciaeriar
12.9 Advanced Molecular-imaging Solution
12.9.1 Company profile
12.9.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.9.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Advanced Molecular-imaging Solution
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NUCLEAR MEDICINE RADIOPHARMACEUTICALS
13.1 Industry Chain of Nuclear Medicine Radiopharmaceuticals
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF NUCLEAR MEDICINE RADIOPHARMACEUTICALS
14.1 Cost Structure Analysis of Nuclear Medicine Radiopharmaceuticals
14.2 Raw Materials Cost Analysis of Nuclear Medicine Radiopharmaceuticals
14.3 Labor Cost Analysis of Nuclear Medicine Radiopharmaceuticals
14.4 Manufacturing Expenses Analysis of Nuclear Medicine Radiopharmaceuticals
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Nuclear Medicine Radiopharmaceuticals in This Report
1.2 Commercial Types of Nuclear Medicine Radiopharmaceuticals
1.2.1 Diagnostic
1.2.2 Brachytherapy
1.2.3 Other Therapeutic
1.3 Downstream Application of Nuclear Medicine Radiopharmaceuticals
1.3.1 Oncology
1.3.2 Thyroid
1.3.3 Cardiology
1.3.4 Others
1.4 Development History of Nuclear Medicine Radiopharmaceuticals
1.5 Market Status and Trend of Nuclear Medicine Radiopharmaceuticals 2013-2023
1.5.1 Global Nuclear Medicine Radiopharmaceuticals Market Status and Trend 2013-2023
1.5.2 Regional Nuclear Medicine Radiopharmaceuticals Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Nuclear Medicine Radiopharmaceuticals 2013-2017
2.2 Sales Market of Nuclear Medicine Radiopharmaceuticals by Regions
2.2.1 Sales Volume of Nuclear Medicine Radiopharmaceuticals by Regions
2.2.2 Sales Value of Nuclear Medicine Radiopharmaceuticals by Regions
2.3 Production Market of Nuclear Medicine Radiopharmaceuticals by Regions
2.4 Global Market Forecast of Nuclear Medicine Radiopharmaceuticals 2018-2023
2.4.1 Global Market Forecast of Nuclear Medicine Radiopharmaceuticals 2018-2023
2.4.2 Market Forecast of Nuclear Medicine Radiopharmaceuticals by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Nuclear Medicine Radiopharmaceuticals by Types
3.2 Sales Value of Nuclear Medicine Radiopharmaceuticals by Types
3.3 Market Forecast of Nuclear Medicine Radiopharmaceuticals by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Nuclear Medicine Radiopharmaceuticals by Downstream Industry
4.2 Global Market Forecast of Nuclear Medicine Radiopharmaceuticals by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Nuclear Medicine Radiopharmaceuticals Market Status by Countries
5.1.1 North America Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
5.1.2 North America Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
5.1.3 United States Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
5.1.4 Canada Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
5.1.5 Mexico Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
5.2 North America Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
5.3 North America Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
5.3.1 North America Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
5.3.2 North America Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
5.4 North America Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Nuclear Medicine Radiopharmaceuticals Market Status by Countries
6.1.1 Europe Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
6.1.2 Europe Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
6.1.3 Germany Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.4 UK Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.5 France Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.6 Italy Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.7 Russia Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.8 Spain Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.1.9 Benelux Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
6.2 Europe Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
6.3 Europe Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
6.3.1 Europe Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
6.3.2 Europe Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
6.4 Europe Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Nuclear Medicine Radiopharmaceuticals Market Status by Countries
7.1.1 Asia Pacific Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
7.1.2 Asia Pacific Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
7.1.3 China Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.1.4 Japan Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.1.5 India Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.1.6 Southeast Asia Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.1.7 Australia Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
7.2 Asia Pacific Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
7.3 Asia Pacific Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
7.3.1 Asia Pacific Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
7.3.2 Asia Pacific Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
7.4 Asia Pacific Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Nuclear Medicine Radiopharmaceuticals Market Status by Countries
8.1.1 Latin America Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
8.1.2 Latin America Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
8.1.3 Brazil Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
8.1.4 Argentina Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
8.1.5 Colombia Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
8.2 Latin America Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
8.3 Latin America Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
8.3.1 Latin America Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
8.3.2 Latin America Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
8.4 Latin America Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market Status by Countries
9.1.1 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Revenue by Countries (2013-2017)
9.1.3 Middle East Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
9.1.4 Africa Nuclear Medicine Radiopharmaceuticals Market Status (2013-2017)
9.2 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market Status by Manufacturers
9.3 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Sales by Type (2013-2017)
9.3.2 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Revenue by Type (2013-2017)
9.4 Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF NUCLEAR MEDICINE RADIOPHARMACEUTICALS
10.1 Global Economy Situation and Trend Overview
10.2 Nuclear Medicine Radiopharmaceuticals Downstream Industry Situation and Trend Overview
CHAPTER 11 NUCLEAR MEDICINE RADIOPHARMACEUTICALS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Nuclear Medicine Radiopharmaceuticals by Major Manufacturers
11.2 Production Value of Nuclear Medicine Radiopharmaceuticals by Major Manufacturers
11.3 Basic Information of Nuclear Medicine Radiopharmaceuticals by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Nuclear Medicine Radiopharmaceuticals Major Manufacturer
11.3.2 Employees and Revenue Level of Nuclear Medicine Radiopharmaceuticals Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 NUCLEAR MEDICINE RADIOPHARMACEUTICALS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Mallinckrodt
12.1.1 Company profile
12.1.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.1.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Mallinckrodt
12.2 Isorad
12.2.1 Company profile
12.2.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.2.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Isorad
12.3 Cardinal Health
12.3.1 Company profile
12.3.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.3.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Cardinal Health
12.4 Jubilant
12.4.1 Company profile
12.4.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.4.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Jubilant
12.5 Medi-Radiopharma
12.5.1 Company profile
12.5.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.5.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Medi-Radiopharma
12.6 Comecer
12.6.1 Company profile
12.6.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.6.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Comecer
12.7 Jaco
12.7.1 Company profile
12.7.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.7.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Jaco
12.8 Ciaeriar
12.8.1 Company profile
12.8.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.8.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Ciaeriar
12.9 Advanced Molecular-imaging Solution
12.9.1 Company profile
12.9.2 Representative Nuclear Medicine Radiopharmaceuticals Product
12.9.3 Nuclear Medicine Radiopharmaceuticals Sales, Revenue, Price and Gross Margin of Advanced Molecular-imaging Solution
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NUCLEAR MEDICINE RADIOPHARMACEUTICALS
13.1 Industry Chain of Nuclear Medicine Radiopharmaceuticals
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF NUCLEAR MEDICINE RADIOPHARMACEUTICALS
14.1 Cost Structure Analysis of Nuclear Medicine Radiopharmaceuticals
14.2 Raw Materials Cost Analysis of Nuclear Medicine Radiopharmaceuticals
14.3 Labor Cost Analysis of Nuclear Medicine Radiopharmaceuticals
14.4 Manufacturing Expenses Analysis of Nuclear Medicine Radiopharmaceuticals
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
